Matt Simmons 💊
2.2K posts
Matt Simmons 💊
@MatthewHSimmons
Oncology Strategy Lead @IQVIA_Biotech. Opinions my own.
London Katılım Ekim 2011
325 Takip Edilen444 Takipçiler
Sequencing whole genome of newborns will be ‘transformational’ in earlier diagnosis and treatment of rare diseases...
theguardian.com/society/2024/o…
London, England 🇬🇧 English
Matt Simmons 💊 retweetledi
📊 Shifts in global clinical trial distribution: Europe's share declines across most segments, while China sees growth, except in biosimilars. More on these regional trends from our Rethinking Clinical Trial Country Prioritization report: bit.ly/3XE9hAQ. #ClinicalTrials
English
What else is needed in the near-term to change the trajectory of the past five years and increase Europe’s share of global oncology trial sites ? #ESMO24
English
The latest performance data from the UK’s MHRA reveal that clinical trial applications continue to be handled within the target statutory timescales - average of 27 days compared with the statutory timescales of 30 days)
gov.uk/government/pub…
English
Join me at the @IQVIA_Institute multi-stakeholder symposium ahead of #ESMO24 in Barcelona...
events.iqvia.com/event/IQVIAIns…
English
The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing— Challenging the “more is better” dogma journals.sagepub.com/doi/full/10.11…
Richmond, London 🇬🇧 English
Noteworthy advances in oncology R&D shared during #ASCO24 enhancing the art of cancer care and potentially transforming treatment approaches for patients... pharmaphorum.com/oncology/asco-…
Richmond, London 🇬🇧 English
Although careful consideration is necessary to determine which #clinicaltrials in #oncology are well suited for inclusion of pragmatic design features, there is growing momentum to simplify, broaden access and increase generalizability of study data.... ascopubs.org/doi/10.1200/ED…
Lambeth, London 🇬🇧 English
"In Phase I trials, #AI-discovered molecules are substantially more successful than historic industry averages..."
sciencedirect.com/science/articl…
Richmond, London 🇬🇧 English
❓As increasing molecular subtyping continues to turn even some common tumour types a set of rare diseases, is there a way to make just-in-time site activation live up to its promise through reducing the administrative and regulatory burden for sites ?
English
❓How do we turn the real world data often buried in medical notes into real world evidence that is generalizable to bring precision medicine clinical trials to patients ?
English
Some key takeaways:
1️⃣: Multiple targeted agents are available across many different tumours, with many more in development, but most patients just aren’t getting tested and so aren’t getting optimal care…
IQVIA Institute@IQVIA_Institute
🔬Happening Now: IQVIA Institute Pre-ASCO Symposium in Chicago & virtually. We are discussing the future of precision oncology, including clinical trial site selection, recruitment challenges, real-world data needs, testing practices, and ensuring patient access. #Oncology
English